rct
Research Passport
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet (London, England)· 2023-01-28· rct
Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Joe Marion, Emma Ogburn, Julie Allen, Heather Rutter, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, Tracie-Ann Madden, Jane Holmes, Victoria Harris, May Ee Png, Mark Lown, Oliver van Hecke, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Lazaro Mwandigha, Ushma Galal, Sam Mort, Bhautesh D Jani, Nigel D Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Jem Chalk, Layla Lavallee, Elizabeth Hadley, Lucy Cureton, Magdalena Benysek, Monique Andersson, Maria Coates, Sarah Barrett, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Andrew Carson-Stevens, Ly-Mee Yu, Paul Little, Unknown
Stage: unknownIntegrity: okDOI: 10.1016/s0140-6736(22)02597-1PMID: 36566761PMCID: PMC9779781
PharmaLens analyzed the title, abstract, and available metadata—not the full text.
Discuss this paperOpens the Paper Discussion Hub (community opinions are not article intelligence)
Study design
Verified findings
numeric_findings[2]
{"unit":null,"label":"reported_value","value_text":"8"}
View evidence
FINDINGS · FINDINGS:S001
“”
numeric_findings[3]
{"unit":null,"label":"reported_value","value_text":"12"}
View evidence
FINDINGS · FINDINGS:S002
“”
numeric_findings[4]
{"unit":null,"label":"reported_value","value_text":"56"}
View evidence
FINDINGS · FINDINGS:S003
“”
population
{"description":"The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of mo","sample_size":null,"exclusion_summary":null,"inclusion_summary":null}
View evidence
BACKGROUND · BACKGROUND:S001
“”
Limitations & not reported
- authors_conclusion
- comparator
- extension.rct_extension.allocation_ratio
- extension.rct_extension.blinding
- extension.rct_extension.itt_or_per_protocol
- extension.rct_extension.primary_endpoint
- extension.rct_extension.randomization_method
- extension.rct_extension.sample_size_arms
- intervention
- key_results
- limitations
- primary_outcome
- safety_findings
AI transparency & provenance
- PharmaLens analyzed the title, abstract, and available metadata—not the full text.
- This page is not medical advice.
- Scores and ranks shown in search are query-relative relevance only — not evidence quality.
- Similarity neighbors do not imply support or contradiction.
- Cover media kind: deterministic_cover
- Extraction schema: pharmalens.article-intelligence.v1
- Revision: 1
Cite this page
Related research
- Lecanemab in Early Alzheimer's Disease.
- Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
- Evidence Neighborhood preview: Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
- Evidence Neighborhood preview: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Evidence Neighborhood preview: Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
- Evidence Neighborhood preview: Lecanemab in Early Alzheimer's Disease.
Relatedness is similarity or shared entities — not support or contradiction.